Search

Your search keyword '"Fan, Ruitai"' showing total 263 results
Start Over Author "Fan, Ruitai"
263 results on '"Fan, Ruitai"'

7. Cuproptosis, the novel type of oxidation-induced cell death in thoracic cancers: can it enhance the success of immunotherapy?

Author

Zhao, Ruiwen, Sukocheva, Olga, Tse, Edmund, Neganova, Margarita, Aleksandrova, Yulia, Zheng, Yufei, Gu, Hao, Zhao, Deyao, Madhunapantula, SabbaRao V., Zhu, Xiaorong, Liu, Junqi, and Fan, Ruitai

Subjects
CELL death, APOPTOSIS, LIPOIC acid, COPPER, IMMUNOTHERAPY
Abstract

Copper is an important metal micronutrient, required for the balanced growth and normal physiological functions of human organism. Copper-related toxicity and dysbalanced metabolism were associated with the disruption of intracellular respiration and the development of various diseases, including cancer. Notably, copper-induced cell death was defined as cuproptosis which was also observed in malignant cells, representing an attractive anti-cancer instrument. Excess of intracellular copper leads to the aggregation of lipoylation proteins and toxic stress, ultimately resulting in the activation of cell death. Differential expression of cuproptosis-related genes was detected in normal and malignant tissues. Cuproptosis-related genes were also linked to the regulation of oxidative stress, immune cell responses, and composition of tumor microenvironment. Activation of cuproptosis was associated with increased expression of redox-metabolism-regulating genes, such as ferredoxin 1 (FDX1), lipoic acid synthetase (LIAS), lipoyltransferase 1 (LIPT1), dihydrolipoamide dehydrogenase (DLD), drolipoamide S-acetyltransferase (DLAT), pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1), and pyruvate dehydrogenase E1 subunit beta (PDHB)). Accordingly, copper-activated network was suggested as an attractive target in cancer therapy. Mechanisms of cuproptosis and regulation of cuproptosis-related genes in different cancers and tumor microenvironment are discussed in this study. The analysis of current findings indicates that therapeutic regulation of copper signaling, and activation of cuproptosis-related targets may provide an effective tool for the improvement of immunotherapy regimens. Key messages: Facts • Copper ions, essential components of human body, can activate a novel subtype of programmed cell death, defined as cuproptosis. • Cuproptosis is tightly associated with the regulation of mitochondrial respiration and oxidative stress in various cells, including malignant. • Changed concentration of copper ions was found to regulate a set of redox-metabolism-regulating genes, such as ferredoxin 1, lipoic acid synthetase, lipoyltransferase 1, dihydrolipoamide dehydrogenase, drolipoamide S-acetyltransferase, and pyruvate dehydrogenase E1 subunits alpha 1 and beta. • Cuproptosis-related genes and copper-containing compounds were indicated as potential targets and tools for the development of novel anti-cancer therapy. Open Questions • How to target cuproptosis-related genes to stop cancer cell survival? • Which copper-responsive targets and/or copper-containing compounds can be employed safely and effectively during cancer treatment? • Which biomarkers can be reliably employed to define good response to the activation of cuproptosis in cancer cells? • Are there others, undiscovered intracellular targets of copper which can be used for cancer prevention and treatment? [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Inflammation and Stem Cell Stochasticity of HPV-induced Cervical Cancer: Epigenetics Based Biomarkers through Microbiome and Metabolome for Personalized Medicine: A Systematic Review

Author

Zheng, Yufei, primary, Liu, Junqi, additional, Beeraka, Narasimha M, additional, Manogaran, Prasath, additional, Vikram P R, Hemanth, additional, YN, Lakshmi Durga, additional, Suhail, Shaik Mohammed, additional, Pradeepkumar, Bhupalam, additional, Sinelnikov, Mikhail Y, additional, Greeshma, MV, additional, P A, Mahesh, additional, MP, Namratha, additional, Bannimath, Gurupadayya, additional, Zhao, Jie, additional, and Fan, Ruitai, additional

Published
2023
Full Text
View/download PDF

15. Screening fructosamine-3-kinase (FN3K) inhibitors, a deglycating enzyme of oncogenic Nrf2: Human FN3K homology modelling, docking and molecular dynamics simulations

Author

Beeraka, Narasimha M., primary, Zhang, Jin, additional, Mandal, Subhankar, additional, Vikram P. R., Hemanth, additional, Liu, Junqi, additional, B. M., Namitha, additional, Zhao, Di, additional, Vishwanath, Prashanth, additional, B. M., Gurupadayya, additional, and Fan, Ruitai, additional

Published
2023
Full Text
View/download PDF

18. Chinese Clinical Trial Registry 13-year data collection and analysis: geographic distribution, financial support, research phase, duration, and disease categories

Author

Fan, Ruitai, primary, Zheng, Yufei, additional, Zhou, Runze, additional, Beeraka, Narasimha M., additional, Sukocheva, Olga A., additional, Zhao, Ruiwen, additional, Li, Shijie, additional, Zhao, Xiang, additional, Liu, Chunying, additional, He, Song, additional, Mahesh, P. A., additional, Gurupadayya, B. M., additional, Nikolenko, Vladimir N., additional, Zhao, Di, additional, and Liu, Junqi, additional

Published
2023
Full Text
View/download PDF

22. Application of COMPASS 3D Dose Validation System in Volumetric Modulated Arc Therapy of Esophageal Cancer

Author

WANG Xiaomin, TANG Guang, GU Hao, ZHAO Yidian, WANG Haiyang, and FAN Ruitai

Subjects
compass 3d validation system, esophageal cancer, volumetric modulated arc therapy, dose verification, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Objective To explore the feasibility of COMPASS 3D dose verification system in volumetric modulated arc therapy of esophageal cancer. Methods We selected 37 patients newly diagnosed as esophageal neoplasm to make VMAT design based on the Oncentra planning system, and then transferred the treatment plan to the COMPASS validation system and the accelerator.We compared the calculated results in the planned system with the actual measurements in the COMPASS validation system.We obtained the Gamma passing rate, separately D95 and Dmean of the gross tumor volume(GTV) and the planning target volume(PTV), and compared the V20 and V30 dose values of the total lung. Results The calculated results and the measured results of the γ pass rate were higher than 92% respectively.The average dose difference for D95 was less than 3% for most treatment plans and the average difference for the target volumes(Dmean) was less than 1%.The average difference for V20 and V30 of the total lung were (9.86±2.18, 20.03±2.21)% and (12.35±2.61, 12.40±2.52)% in the calculated results and the measured results, respectively. Conclusion COMPASS 3D validation system could analyze the results accurately and quickly, ensure the safety of esophageal cancer treatment.

Published
2018
Full Text
View/download PDF

23. Combinatorial Implications of Nrf2 Inhibitors with FN3K Inhibitor: In vitro Breast Cancer Study

Author

Beeraka, Narasimha M., primary, Zhang, Jin, additional, Zhao, Di, additional, Liu, Junqi, additional, A U, Chinnappa, additional, Vikram PR, Hemanth, additional, Shivaprakash, Priyanka, additional, Bannimath, Namitha, additional, Manogaran, Prasath, additional, Sinelnikov, Mikhail Y., additional, Bannimath, Gurupadayya, additional, and Fan, Ruitai, additional

Published
2023
Full Text
View/download PDF

24. A Recent Update on the Epigenetic Repertoire and Chromatin Modifying Therapy in Diabetes Mellitus: A Comprehensive Review

Author

Beeraka, Narasimha Murthy, primary, Fan, Ruitai, primary, Wang, Xin, additional, Zhao, Di, additional, Tatineni, Spandana, additional, Sri, Chiriki Devi, additional, Nishanth, Veera Venkata, additional, Uthiah, Chinnappa Apatira, additional, Leihang, Zonunsiami, additional, Sugur, Kavya, additional, Liu, Junqi, additional, and Nikolenko, Vladimir Nikolaevich, additional

Published
2023
Full Text
View/download PDF

27. Incidence Trends, Clinicopathologic Characteristics, and Overall Survival Prediction in Retinoblastoma Children: SEER Prognostic Nomogram Analysis.

Author

Guo, Xiaohong, Wang, Li, Beeraka, Narasimha M, Liu, Chunying, Zhao, Xiang, Zhou, Runze, Yu, Huiming, Fan, Ruitai, and Liu, Junqi

Subjects
REPORTING of diseases, RESEARCH, CEREBRAL dominance, CONFIDENCE intervals, DISEASE incidence, REGRESSION analysis, CANCER patients, RESEARCH funding, RETINOBLASTOMA, PREDICTION models, RESIDENTIAL patterns, STATISTICAL correlation, OVERALL survival, PROPORTIONAL hazards models, SYMPTOMS, CHILDREN
Abstract

Background Retinoblastoma is the most common intraocular malignant tumor occurring among children, with an incidence rate of 1/15 000. This study built a joinpoint regression model to assess the incidence trend of retinoblastoma from 2004 to 2015 and constructed a nomogram to predict the overall survival (OS) in children. Materials and Methods Patients less than 19 years diagnosed with retinoblastoma from 2004 to 2015 were selected from the SEER database. Joinpoint regression analysis (version 4.9.0.0) was performed to evaluate the trends in retinoblastoma incidence rates from 2004 to 2015. Cox Regression Analysis was applied to investigate prognostic risk factors that influence OS. Results Joinpoint regression revealed that retinoblastoma incidence exhibited no significant increase or decrease from 2004 to 2015. As per the multiple Cox regression, tumor size, laterality, and residence (rural-urban continuum code) were correlated with OS and were used to construct a nomogram. The nomogram exhibited a good C-index of 0.71 (95% CI, 0.63 to 0.79), and the calibration curve for survival probability demonstrated that the predictions corresponded well with actual observations. Conclusions and Relevance A prognostic nomogram integrating the risk factors for retinoblastoma was constructed to provide comparatively accurate individual survival predictions. If validated, this type of assessment could be used to guide therapy in patients with retinoblastoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Comparative pharmacological efficacy of COVID-19 vaccines against the variants of concerns (VOCs) of SARS-CoV-2: Recent clinical Studies on Booster dose

Author

Fan, Ruitai, primary, Zhao, Di, additional, Wang, Xiaoyan, additional, Liu, Junqi, additional, AU, Chinnappa, additional, Basavaraj, Vijaya, additional, Devi Sri, Chiriki, additional, Nikolenko, Vladimir N., additional, Beeraka, Narasimha M., additional, and Sivaprakash, Priyanka, additional

Published
2023
Full Text
View/download PDF

37. Corrigendum to “Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers” [Semin. Cancer Biol. 83 (2022) 556–569]

Author

Chen, Kuo, primary, Lu, Pengwei, additional, Beeraka, Narasimha M., additional, Sukocheva, Olga A., additional, Madhunapantula, SubbaRao V., additional, Liu, Junqi, additional, Sinelnikov, Mikhail Y., additional, Nikolenko, Vladimir N., additional, Bulygin, Kirill V., additional, Mikhaleva, Liudmila M., additional, Reshetov, Igor V., additional, Gu, Yuanting, additional, Zhang, Jin, additional, Cao, Yu, additional, Somasundaram, Siva G., additional, Kirkland, Cecil E., additional, Fan, Ruitai, additional, and Aliev, Gjumrakch, additional

Published
2022
Full Text
View/download PDF

40. Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers

Author

Chen, Kuo, primary, Lu, Pengwei, additional, Beeraka, Narasimha M., additional, Sukocheva, Olga A., additional, Madhunapantula, SubbaRao V., additional, Liu, Junqi, additional, Sinelnikov, Mikhail Y., additional, Nikolenko, Vladimir N., additional, Bulygin, Kirill V., additional, Mikhaleva, Liudmila M., additional, Reshetov, Igor V., additional, Gu, Yuanting, additional, Zhang, Jin, additional, Cao, Yu, additional, Somasundaram, Siva G., additional, Kirkland, Cecil E., additional, Fan, Ruitai, additional, and Aliev, Gjumrakch, additional

Published
2022
Full Text
View/download PDF

42. Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers

Author

Chen, Kuo, primary, Zhang, Jin, additional, Beeraka, Narasimha M., additional, Tang, Chengyun, additional, Babayeva, Yulia V., additional, Sinelnikov, Mikhail Y., additional, Zhang, Xinliang, additional, Zhang, Jiacheng, additional, Liu, Junqi, additional, Reshetov, Igor V., additional, Sukocheva, Olga A., additional, Lu, Pengwei, additional, and Fan, Ruitai, additional

Published
2022
Full Text
View/download PDF

43. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study).

Author

Meng, Xue, primary, Zheng, Anping, additional, Wang, Jun, additional, Wang, Jianhua, additional, Li, Guang, additional, Zhu, Jun, additional, Ma, Hu, additional, Zhu, Xiaodong, additional, Shi, Anhui, additional, Dai, Chunhua, additional, Yan, Senxiang, additional, Wang, Buhai, additional, Qu, Zhongyu, additional, Han, Chun, additional, Sun, Xindong, additional, Ye, Ming, additional, Fan, Ruitai, additional, Huerxidan, Ni yazi, additional, Wang, Xiaohong, additional, and Yu, Jinming, additional

Published
2022
Full Text
View/download PDF

44. COVID-19 Effects on Geriatric Population and Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccines in the Prevention and Treatment of COVID-19

Author

Beeraka, Narasimha M., primary, Tulimilli, SubbaRao V., additional, Greeshma, Mandya V., additional, Dallavalasa, Siva, additional, Zhang, Yaowen, additional, Xiao, Wenjing, additional, Fan, Ruitai, additional, Zhao, Di, additional, Bettadapura, Anjali D.S., additional, Nataraj, Suma M., additional, Madhunapantula, SubbaRao V., additional, and Liu, Junqi, additional

Published
2022
Full Text
View/download PDF

45. Immune Repertoire and Advancements in Nanotherapeutics for the Impediment of Severe Steroid Resistant Asthma (SSR)

Author

Beeraka,Narasimha M, Zhou,Runze, Wang,Xiaoyan, Vikram P R,Hemanth, Kumar,Tegginamath Pramod, Liu,Junqi, Greeshma,M V, Mandal,Subhankar P, Gurupadayya,B M, and Fan,Ruitai

Subjects
International Journal of Nanomedicine
Abstract

Narasimha M Beeraka,1– 3 Runze Zhou,1 Xiaoyan Wang,4 Hemanth Vikram P R,5 Tegginamath Pramod Kumar,6 Junqi Liu,1 M V Greeshma,3 Subhankar P Mandal,5 B M Gurupadayya,1 Ruitai Fan1 1Department of Radiation Oncology, Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China; 2Department of Human Anatomy, Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119991, Russia; 3Center of Excellence in Molecular Biology and Regenerative Medicine (CEMR), Department of Biochemistry, JSS Academy of Higher Education and Research (JSS AHER), JSS Medical college, Mysuru, Karnataka, India; 4Endocrinology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China; 5Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSSAHER), Mysuru, 570015, Karnataka, India; 6Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research (JSSAHER), Mysore, Karnataka, 570015, IndiaCorrespondence: Ruitai Fan, Department of Radiation Oncology, Cancer Center, The First Affiliated Hospital of Zhengzhou University, 1 Jianshedong Str., Zhengzhou, 450052, People’s Republic of China, Email fccfanrt@zzu.edu.cnAbstract: Severe steroid-resistant asthma (SSR) patients do not respond to the corticosteroid therapies due to the heterogeneity, and genome-wide variations. However, there are very limited reports pertinent to the molecular signaling underlying SSR and making pharmacologists, and formulation scientists to identify the effective therapeutic targets in order to produce novel therapies using novel drug delivery systems (NDDS). We have substantially searched literature for the peer-reviewed and published reports delineating the role of glucocorticoid-altered gene expression, and the mechanisms responsible for SSR asthma, and NDDS for treating SSR asthma using public databases PubMed, National Library of Medicine (NLM), google scholar, and medline. Subsequently, we described reports underlying the SSR pathophysiology through several immunological and inflammatory phenotypes. Furthermore, various therapeutic strategies and the role of signaling pathways such as mORC1-STAT3-FGFBP1, NLRP3 inflammasomes, miR-21/PI3K/HDAC2 axis, PI3K were delineated and these can be considered as the therapeutic targets for mitigating the pathophysiology of SSR asthma. Finally, the possibility of nanomedicine-based formulation and their applications in order to enhance the long term retention of several antioxidant and anti-asthmatic drug molecules as a significant therapeutic modality against SSR asthma was described vividly.Graphical Abstract: Keywords: natural products, steroid resistance, asthma, inflammation, molecular signaling, nanomedicine, novel drug delivery systems

Published
2022

46. Perspectives on the nanocarriers with miRNAs for targeting melanoma stemness through epigenetic regulation.

Author

Junqi Liu, Jin Zhang, Beeraka, Narasimha M., Kuo Chen, Sinelnikov, Mikhail Y., Manogaran, Prasath, Bannimath, Gurupadayya, Nikolenko, Vladimir N., and Fan, Ruitai

Subjects
MICRORNA, NANOCARRIERS, EPIGENETICS, MELANOMA, GENE therapy
Abstract

Several research reports delineated the significant role of miRNAs in cancer proliferation, and their modulatory role in cancer mitigation, and drug resistance. Melanoma cells have been acquiring stemness to several chemotherapeutic agents through drug efflux proteins, epigenetic modulation, and DNA repair. miRNAs could be applied as novel therapeutic modalities for treating several kinds of cancers to modulate these mechanisms involved in stemness. Nanocarriers to carry these tumor-targeting miRNAs to modulate stemness are a prominent strategy to overcome their low penetrability, minimal stability, and nonspecificity. We have searched several public databases such as PubMed, Medline, Google scholar, and NLM and obtained the information pertinent to the miRNA-based nanocarrier systems to target stemness through epigenetic modulation in melanomas. This review delineates that various miRNAs can modulate the stemness in melanomas by specific intricate epigenetic signaling, and other cell-based signaling mechanisms. Specific nanocarrier formulations with specific miRNAs are optimal methods to deliver these miRNAs in order to achieve significant entrapment efficiency, loading efficiency, and stability. Furthermore, the combinatorial regimen of FDA-approved chemotherapeutic molecules with tumor-targeting miRNAs and chemotherapy combined with nanocarriers can efficiently deliver the utmost therapeutic window by targeting tumor matrix, invasion, metastasis, and angiogenesis in melanomas. Substantial research should focus on the clinical application of this gene therapy in melanomas using these low immunogenic, highly degradable, and biocompatible combinatorial nanotherapeutic regimens. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial

Author

Liu, Yun, primary, Beeraka, Narasimha M, additional, Liu, Junqi, additional, Chen, Kuo, additional, Song, Bo, additional, Song, Zhang, additional, Luo, Jianchao, additional, Liu, Yang, additional, Zheng, Anping, additional, Cui, Yanhui, additional, Wang, Yang, additional, Jia, Zhenhe, additional, Song, Xiangyu, additional, Wang, Xiaohong, additional, Wang, Hongqi, additional, Qi, Xuefeng, additional, Ren, Jinshan, additional, Wu, Liping, additional, Cai, Jixing, additional, Fang, Xainying, additional, Wang, Xin, additional, Sinelnikov, Mikhail Y, additional, Nikolenko, Vladimir N, additional, Greeshma, M V, additional, and Fan, Ruitai, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results